Anti-diabetic effects of cesium aqua (N,N'-ethylene(salicylideneiminato)-5-sulfonato) oxovanadium (IV) dihydrate in streptozotocin-induced diabetic rats.
The study has been designed to investigate the anti-diabetic effects of cesium aqua (N,N'-ethylene (salicylideneiminato)-5-sulfonato) oxovanadium (IV) dihydrate (VO(salen-SO(3))), an organic vanadium compound, in streptozotocin-induced diabetic rats. VO(salen-SO(3)) was orally administrated to diabetic rats at the dose of 0.3 mg/ml through drinking water for 24 days. Blood glucose level was significantly declined, and oral glucose tolerance was improved after VO(salen-SO(3)) treatment. Moreover, liver and muscle glycogen concentrations were markedly increased in VO(salen-SO(3))-treated diabetic rats. On the other hand, aspartate amino transferase and blood urea nitrogen in serum were significantly decreased after treatment with VO(salen-SO(3)). Taken together, these results suggested that VO(salen-SO(3)) may be of potential value in the therapy of diabetic symptom and hyperglycemia-induced hepatic and renal dysfunction.
Li
Ming
M
College of Life Science, Graduate University of Chinese Academy of Sciences, Beijing, China.
Wei
Dan
D
Ding
Wenjun
W
Baruah
Bharat
B
Crans
Debbie C
DC
D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001806:Blood Urea Nitrogen; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D006003:Glycogen / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D015394:Molecular Structure; D009132:Muscles / Q000187:drug effects / Q000378:metabolism; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D014638:Vanadates / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*
C529421:(N,N'-ethylene(salicylideneiminato)-5-sulfonato)oxovanadium (IV) dihydrate; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D009942:Organometallic Compounds; C075743:oxovanadium IV; D014638:Vanadates; D013311:Streptozocin; D006003:Glycogen; D001219:Aspartate Aminotransferases